4-(5'-METHYL-2'-PHENYL-1H-INDOL-3'-YL)-6-HYDRAZINO-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-AMINE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	UKXQDAUNVKLETP-UHFFFAOYSA-N
Smiles	Cc1ccc2[nH]c(c3ccccc3)c(c4nc(NN)nc5[nH]nc(N)c45)c2c1
InChI	InChI=1S/C20H18N8/c1-10-7-8-13-12(9-10)14(16(23-13)11-5-3-2-4-6-11)17-15-18(21)27-28-19(15)25-20(24-17)26-22/h2-9,23H,22H2,1H3,(H4,21,24,25,26,27,28)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C20H18N8
Molecular Weight	370.41
AlogP	4.02
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	5.0
Number of Rotational Bond	3.0
Polar Surface Area	134.32
Molecular species	NEUTRAL
Aromatic Rings	5.0
Heavy Atoms	28.0

Assay Description	Organism	Bioactivity
Antifungal activity against Aspergillus terreus at 1 mg/ml after 72 hr by agar well diffusion method	Aspergillus terreus	10.0 mm
Antifungal activity against Aspergillus niger at 1 mg/ml after 72 hr by agar well diffusion method	Aspergillus niger	10.0 mm
Antifungal activity against Aspergillus oryzae at 1 mg/ml after 72 hr by agar well diffusion method	Aspergillus oryzae	9.0 mm
Antibacterial activity against Klebsiella pneumoniae at 1 mg/ml after 24 hr by agar well diffusion method	Klebsiella pneumoniae	13.0 mm
Antibacterial activity against Pseudomonas aeruginosa at 1 mg/ml after 24 hr by agar well diffusion method	Pseudomonas aeruginosa	12.0 mm
Antibacterial activity against Staphylococcus aureus at 1 mg/ml after 24 hr by agar well diffusion method	Staphylococcus aureus	11.0 mm

Cross References

Resources	Reference
ChEMBL	CHEMBL2259889
PubChem	76315545

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).